BMW's Small, Carbon-Laden Superbike Emerged at Villa d'Este
At the illustrious Concorso d'Eleganza Villa d'Este at Lake Como, BMW has provided a rare early glimpse into its next-generation superbike. The BMW Motorrad Concept RR represents a new direction for the automaker, setting a new standard for construction and aerodynamics for its superbike lineup. The aim is to have a flagship, zero-compromise superbike in the lineup, and this may be BMW's best effort yet.
Paying particular attention to aerodynamics and the demands placed on a superbike and its rider, Concept RR is not only lightweight and performant, but it's compact, too. BMW also culled many external attachments to further focus on airflow around the bike and rider, and improved airflow through the bike itself to increase airflow to the rear winglets of the bike.
Focusing on "riding stability at very high speeds" and the Concept RR's ability to handle cornering at high speeds, BMW engineers knew they'd have to reduce air resistance in every possible way. BMW utilized carbon and aluminum throughout, materials renowned for their stability and strength while remaining lightweight. Where BMW engineers didn't eliminate, like with the external attachments, they innovated. The frame and every component on the bike, for example, were "optimized for lightweight construction and performance."
BMW applied everything learned from the track to the Concept RR. The bike is just as performant beneath the fuel tank but packs all the power and performance from previous generations into a smaller, lighter package. What more could you ask for?
BMW wasn't clear on how much of the bike is carbon, but it seems that many of the body panels are. We know the frame and tail are aluminum, but we don't know where else aluminum may have been incorporated. It's an incredible early look at the Concept RR, but we just wish there were more details. From what we know so far, though, it's an incredible bike.
Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Mitchell Quain Bought 9.6% More Shares In AstroNova
Whilst it may not be a huge deal, we thought it was good to see that the AstroNova, Inc. (NASDAQ:ALOT) Independent Director, Mitchell Quain, recently bought US$91k worth of stock, for US$9.05 per share. However, it only increased their shares held by 9.6%, and it wasn't a huge purchase by absolute value, either. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. In the last twelve months, the biggest single purchase by an insider was when Lead Independent Director Richard Warzala bought US$161k worth of shares at a price of US$8.07 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$9.01. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price. In the last twelve months AstroNova insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! Check out our latest analysis for AstroNova AstroNova is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket. Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that AstroNova insiders own 7.9% of the company, worth about US$5.5m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing! It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on AstroNova stock. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we've found that AstroNova has 3 warning signs (2 don't sit too well with us!) that deserve your attention before going any further with your analysis. Of course AstroNova may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
How Is Hologic's Stock Performance Compared to Other Health Care Equipment Stocks?
With a market cap of $14.3 billion, Hologic, Inc. (HOLX) is a Massachusetts-based medical technology firm, primarily focused on women's health. The company develops, manufactures, and sells a comprehensive suite of solutions, including molecular diagnostics, medical imaging systems, and surgical devices Companies worth $10 billion or more are generally described as 'large-cap stocks,' and Hologic fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical instruments & supplies industry. The company benefits from robust innovation, supported by over 7,000 patents, which fuels its proprietary technologies and product differentiation. Its diagnostics segment, particularly in molecular testing, has shown strong growth, positioning Hologic well in the expanding global healthcare market. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. However, HOLX shares have retreated 24.5% from their 52-week high of $84.67 touched on Aug. 9, 2024. Meanwhile, HOLX stock has surged 3.2% over the past three months, surpassing the SPDR S&P Health Care Equipment ETF's (XHE) 4.8% plunge over the same time frame. HOLX stock has plummeted 11.3% on a YTD basis and 10.5% over the past 52 weeks, compared to XHE's 10.6% dip in 2025 and a 6.3% fall over the past year. The stock has remained consistently below its 200-day moving average since early December last year, but has climbed above its 50-day moving average since late May. On May 27, HOLX shares surged more than 14%, leading S&P 500 gainers, after reports emerged that TPG Inc. (TPG) and Blackstone Inc. (BX) made (and were turned down on) a non-binding ~$16 billion takeover bid, valuing the company at $70–$72 per share. The stock's rally reflected investor optimism and underscored the premium valuation placed on its leadership in women's health and diagnostic capabilities. In the competitive healthcare equipment industry, top rival, Align Technology, Inc.'s (ALGN) 13.7% drop on a YTD basis and 25.7% decline over the past year trails HOLX's losses in the same time frames. Among the 19 analysts covering the HOLX stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $68.27 suggests a 6.7% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Meet the nine private humanoid robot firms shaping the future
The humanoid robot arms race is on, and it's not just Tesla Inc (NASDAQ:TSLA) making noise with its Optimus humanoid—the real action is happening among a new generation of private players, each betting big on a future where humanoids are everywhere from factory floors to your living room, according to UBS analysts. "Understanding what these private companies are working on and tracking their progress can help inform investors about the future/feasibility of the humanoid robot opportunity and use cases such as more plant automation,' UBS analysts said in a recent note, pointing to a wave of start-ups already landing deals with auto giants like BMW (ETR:BMWG) and Mercedes. Figure AI, founded in 2022, is going all-in on autonomous humanoids for manufacturing, logistics, and retail. Figure's BotQ facility can crank out up to 12,000 robots a year, and the company is already using its own robots to build more robots. After a $1.5 billion Series C in May 2025, Figure's valuation soared to $39.5 billion, with its first commercial deal inked with BMW and a second, undisclosed 'major US company' already signed. Between these two customers, Figure believes there's a path to 100,000 robots over the next four years. Agility Robotics, meanwhile, is already deploying its Digit robots in logistics and manufacturing, targeting the more than one million unfilled material handling jobs in the U.S. With partnerships ranging from GXO Logistics Inc (NYSE:GXO) and Schaeffler to Tompkins (NYSE:TMP) Solutions, Agility is scaling up quickly, pushing robots-as-a-service deals and using its Agility Arc platform to control robots in tandem with other equipment. The company recently upgraded Digit's battery life and safety features, and a minority investment from Schaeffler signals growing industry confidence. Collaborative Robotics, or Cobot, is taking a different approach, focusing on AI-driven collaborative robots that work shoulder-to-shoulder with people in shared workspaces such as warehouses, hospitals, and factories. Since their 2024 debut, Cobot's Proxie robots have logged over 5,000 operational hours and moved 16,000 carts in customer facilities. The company is developing cobots that integrate large language models, voice recognition, and speech synthesis to enable dynamic, human-like interaction on the job Apptronik, with roots in NASA, has built Apollo, a robot designed for heavy lifting in manufacturing, logistics, and even healthcare. Commercial deployments began with Mercedes-Benz (OTC:MBGAF) in 2024, and new partnerships with Jabil and Google (NASDAQ:GOOGL) DeepMind are helping scale both production and AI capabilities. Apollo is built to perform physically demanding tasks in industrial spaces, working right alongside humans 1X Technologies is targeting the home, planning large-scale deployment of its Neo humanoid in the U.S. in 2025. The company's acquisition of Kind Humanoid is accelerating its tech development, and 1X is backed by EQT (ST:EQTAB) Ventures. Their focus is on creating an abundant supply of labor via safe, intelligent humanoids, scaling from research and development to full-scale manufacturing The next wave of contenders is equally ambitious. Mentee Robotics is building robots that can be 'mentored' in real time by humans, aiming for personalized, adaptive bots. Skild AI is all about general-purpose robotic intelligence, boasting a $4.7 billion valuation and backing from Amazon (NASDAQ:AMZN) and SoftBank (TYO:9984), with its sights set on construction, manufacturing, and security robots. Foundation Robotics Labs is shipping robots for manufacturing, logistics, domestic, and defense use, with a goal of delivering over 10,000 units in 2026. Plus One Robotics, meanwhile, is the parcel-handling specialist, with over one billion picks and AI-powered warehouse automation already saving customers millions in labor costs. While Tesla may be the face of the humanoid-enabled robot future, UBS suggest the real battleground is among these private upstarts—each racing toward a multi-billion-dollar reality, one robot at a time. Related articles Meet the nine private humanoid robot firms shaping the future Tesla plans $8 billion U.S. investment this fiscal year stocks of the week Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
